Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trading Halts

Piper Jaffray Downgrades Otonomy (OTIC) to NeutralAugust 30, 2017 11:23 AM Otonomy (OTIC) PT Lowered to $9 at Cowen Amid Otividex Failure; Dramatic And Fast Changes NeededAugust 30, 2017 10:44 AM JPMorgan Downgrades Otonomy (OTIC ) to NeutralAugust 30, 2017 9:42 AM UPDATE: Otonomy (OTIC) Plunges Over 77% After Phase 3 Trial of OTIVIDEX FailsAugust 30, 2017 7:33 AM Otonomy (OTIC) to Resume Trading at 7:30 AM ETAugust 30, 2017 7:25 AM Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's DiseaseAugust 30, 2017 7:00 AM Otonomy (OTIC) Halted, News PendingAugust 30, 2017 6:57 AM